Tarsus Pharmaceuticals (TARS) closed at $74.11 on Oct 6, 2026, down 0.5% on the day. The stock is down 18.4% over the past month, up 9.4% over three months, down 9.5% year to date and up 13.7% over the past year. It trades 19.0% below its 52-week high of $91.53 and 37.5% above its 52-week low of $53.89. The close sits above its 50-day moving average ($73.02) and above its 200-day moving average ($68.50).
TARS is scheduled to report earnings on Nov 10, 2026.
Tarsus Pharmaceuticals is scheduled to report on Nov 10, 2026.
Yes — the Oct 6, 2026 close of $74.11 is 8.2% above the 200-day average of $68.50.
TARS closed 19.0% below its 52-week high of $91.53.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
